Correction

This article refers to:

Discovery of novel arylamide derivatives containing piperazine moiety as inhibitors of tubulin polymerisation with potent liver cancer inhibitory activity

Article title: Discovery of novel arylamide derivatives containing piperazine moiety as inhibitors of tubulin polymerization with potent liver cancer inhibitory activity

Authors: Xiao-Yi Shi, Huang Jiao, Jia-Kai Zhang, Xin-Yi Tian, Dan-Feng Guo, Jie Gao, Mei-Qi Jia, Jian Song, Sai-Yang Zhang, Xiang-Jing Fu, Hong-Wei Tang

Journal: Journal of Enzyme Inhibition and Medicinal Chemistry

Bibliometrics: Volume 38, Number 1,

DOI: https://doi.org/10.1080/14756366.2023.2237701

The authors regret the following errors in Figure 5A ∼ C of this article. The authors would like to apologize for any inconvenience caused. The correct version of Figure 5 is as follows:

Figure 5. Compound MY-1121 bind to β-tubulin directly on colchicine binding site. (A&B). EBI competition assay, the affinity of the compound with colchicine binding site was negatively correlated with the level of the tubulin adduct band; (C&D). Alkaline protease assay. Cells were treated with Alkaline Proteinase and different concentration of compound MY-1121. The band signal of β-tubulin was negatively correlated with the ability of Alkaline Protease to hydrolyze β-tubulin. The binding of the compound to β-tubulin was able to inhibit the hydrolysis of β-tubulin by Alkaline Protease.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.